Genmab A/S ADR GMAB

$50.97 -0.99 (-1.91%)

Valuation

Market cap
32,426,104,000
Revenue TTM
$3,720,000,000
Net income TTM
$963,000,000
P/E (trailing)
39.67
P/E (forward)
40.29
Profit margin
25.89%
Debt to equity
0.79

Trading

Volume
2,956,800
Avg volume
4,750,462
Day's range
$50.89 – $52.26
Shares out
624,059,000
Stochastic %K
6%
Beta
0.73
Analysts
Strong Buy
Price target
$60.15

Price

Company profile

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disea...

Show more

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Industry
Biotechnology
Sector
Healthcare
Phone
45 70 20 27 28
Website
https://www.genmab.com
Address
Carl Jacobsens Vej 30, Valby, Copenhagen, Denmark

Latest news

Stocktwits

AbovetheGreenLine Nov 17, 8:26 PM
Swing Trade Buy on the Close for Genmab A/S $GMAB. https://abovethegreenline.com/wp-content/uploads/2021/01/ST-1.jpg https://zpr.io/DJFsVsV
0 replies
SilverEagle Nov 17, 5:31 PM
$FENC so much gas left in the tank. Going to join $XNCR $GMAB for the third 50 plus % gainer the last month.
1 replies
Stekli27 Nov 17, 4:06 PM
$GMAB $KOD $SLS Every catalyst I called on this list has delivered so far: GLOW2 ✅ DAYBREAK ✅ OTLK approval ✅ Two Genmab studies ✅ SELLAS REGAL ✅ A clean sweep on these calls in 2026 😎 One more to watch: Kodiak’s KSI-101 before Christmas. Hoping for a strong finish, let the data speak! 🎄🧬
0 replies
H143capital Nov 17, 5:45 AM
#BBIO I’m bullish, but I want the business to earn that conviction. What I’m watching: Attruby’s commercial execution, progress across BBP-418, infigratinib and encaleret, and how management funds the next chapter. $VRDN $GMAB $CGON $ABVX $ARWR My latest deep dive covers the opportunity alongside the risks to shareholders. Read it and tell me what you’re watching. https://h143capital.substack.com/p/bridgebio-pharma-surviving-was-just
0 replies
Merlintrader Nov 14, 10:38 PM
$GMAB Nov 10: Genmab announced a capital increase of 164,828 shares following employee warrant exercises, with expected proceeds of approximately 369.7 million Danish kroner. Finalization was expected after registration. Not investment advice. Full context in our $GMAB stock hub: https://www.merlintrader.com/genmab-gmab-stock-hub/
0 replies
SilverEagle Nov 12, 5:21 PM
$FENC gonna be the 3rd 50+ percenter I’ll give you over the last month. $GMAB $XNCR
0 replies
sneekon Nov 11, 12:44 AM
$GMAB price doesn't hold sell into rally's
0 replies
French_Vibe Nov 10, 11:40 AM
$HALO I checked the last presentation, and there is no mention of Petosemtamab. We can expect around 2% of royalties on the SC form (following the deal with Merus, acquired by $GMAB), and the peak sales of Peto are conservatively estimated between $4-5B (probably between 2030-2035). So it could add $80M-$100M of royalties to Halozyme.
0 replies